↓ Skip to main content

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
5 news outlets
twitter
7 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
Published in
Journal for Immunotherapy of Cancer, January 2019
DOI 10.1186/s40425-018-0470-3
Pubmed ID
Authors

Kerstin Kapp, Barbara Volz, Michael A. Curran, Detlef Oswald, Burghardt Wittig, Manuel Schmidt

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Professor 2 33%
Student > Bachelor 1 17%
Researcher 1 17%
Other 1 17%
Unknown 1 17%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 1 17%
Nursing and Health Professions 1 17%
Economics, Econometrics and Finance 1 17%
Psychology 1 17%
Medicine and Dentistry 1 17%
Other 0 0%
Unknown 1 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 43. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2020.
All research outputs
#522,348
of 15,949,522 outputs
Outputs from Journal for Immunotherapy of Cancer
#61
of 1,310 outputs
Outputs of similar age
#20,669
of 387,049 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#11
of 155 outputs
Altmetric has tracked 15,949,522 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,310 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 387,049 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 155 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.